Go online to PeerView.com/HYJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibodies have allowed clinicians to bring their “A” game when managing multiple myeloma (MM). To see how this happened, watch this activity, developed in collaboration with HealthTree Foundation, to view how experts have rapidly integrated CD38, SLAMF7, and BCMA antibodies into the management of newly diagnosed and relapsed/refractory disease. Each case-based lecture also includes a video testimonial from a patient with MM on how treatment with novel antibodies has made a difference in their lives. Upon completion of this CE activity, participants will be able to: Cite updated evidence on the use of novel antibody platforms targeting CD38, SLAMF7, and BCMA in NDMM and RRMM, Integrate antibody-based therapies, including triplet and quadruplet regimens, into the management of patients with NDMM, Recommend appropriate antibody options for the management of RRMM, including for patients with early relapse or heavily pretreated disease, Develop strategies addressing practical aspects of antibody therapy in MM, including issues related to dosing/scheduling and unique safety considerations, such as neutropenia, infection, and ocular toxicity.